The California-based nonprofit founded by the former 23andMe CEO is set to close the $305 million deal in coming weeks.

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...

Beleaguered genetic testing company 23andMe announced Friday that it has reached an agreement to sell itself to TTAM Research ...

Regeneron is backing away from buying the DNA-testing company after a nonprofit controlled by co-founder Wojcicki made a ...

"There are only a handful of people in the world who have experience in running a direct-to-consumer genetic testing company ...

TTAM replaces biotech company Regeneron as 23andMe's buyer. Last month, Regeneron won the bidding during the bankruptcy ...

A nonprofit run by Anne Wojcicki, the cofounder and former CEO of 23andme, has agreed to buy the genetic testing company for ...

Since filing for bankruptcy, 23andMe officials said that they have received 1.9 million requests from customers to delete their genetic data.

The genetic testing company 23andMe is poised to be sold to a nonprofit run by the company's former chief executive Anne ...

Although TTAM's $305 million offer has been accepted, the deal is not yet finalized. Approval from the U.S. Bankruptcy Court for the Eastern District of Missouri is still pending, with a hearing ...

Anne Wojcicki’s winning bid to reclaim control of 23andMe doesn’t necessarily end the fight over what happens to the DNA of ...

Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron ...